BSD Medical Corporation (NASDAQ: BSDM) today announced that the German Society of Radiation Oncology (DEGRO) has published quality assurance guidelines for deep hyperthermia that support the advanced phased array technology utilized in the BSD-2000 Hyperthermia System. The press release from DEGRO states that the addition of hyperthermia to standard radiotherapy and/or chemotherapy improves the outcome for patients with high risk sarcomas, breast cancer recurrence, superficial tumors, head and neck cancer, cervical cancer, pancreatic cancer, bladder cancer, and rectal cancer. The press release explains that DEGRO is issuing quality assurance guidelines for deep hyperthermia equipment that have been agreed on by a consortium of treatment centers and that the guidelines are expected to improve the delivery of deep hyperthermia. The BSD-2000 Hyperthermia System provides the quality assurance and treatment delivery requirements included in the DEGRO press release for effective delivery of deep hyperthermia.
The German Society of Radiation Oncology (DEGRO – Deutsche Gesellschaft für Radio-Onkologie) is the largest radiation oncology organization in Germany and has more than 2,500 members. The world’s longest running scientific journal in radiation oncology, “Strahlentherapie und Onkologie,” is the official publication of DEGRO.
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.